The timing of chemotherapy and surgery for the treatment of colorectal liver metastases

Clinical Colorectal Cancer

Volumn 9, Issue 4, 2010, Pages 212-218

  Nordlinger, Bernard ^a   Vauthey, Jean Nicolas ^b   Poston, Graeme ^c   Benoist, Stephane ^a   Rougier, Philippe ^a   Cutsem, Eric Van ^d  

^a Section of Radiology   (France)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; FOLFOXIRI; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; HEPATITIS; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; STEATOSIS; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR LESION; WOUND HEALING;

EID: 77957818218     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.031     Document Type: Review

References (72)

1. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42:2212-21.
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorec-tal cancer is associated with adoption of hepatic resection and improved chemo-therapy J Clin Oncol 2009; 27:3677-83.
3. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unre-sectable liver metastases. Ann Oncol 2003; 14(suppl 2):ii13-6.
4. Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43:2037-45.
5. Bathe OF, Ernst S, Sutherland FR, et al. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 2009; 9:156.
6. Gruenberger B, Scheithauer W, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metasta-ses. BMC Cancer 2008; 8:120.
7. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007-16.
8. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-9.
9. Abad A, Massuti B, Antón A, et al. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol 2008; 47:286-92.
10. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovo-rin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243-9.
11. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemo-therapy for unresectable liver metastases. Br J Cancer 2007; 97:1035-9.
12. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 1996; 224:509, discussion 520-2.
13. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-6.
14. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unre-sectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery Ann Oncol 1999; 10:663-9.
15. Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 2005; 22:303-12.
16. Masi G, Vasile E, Loupakis F, et al. Triplet combination of fluoropyrimidines, ox-aliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7:7-14.
17. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9.
18. Seium Y, Stupp R, Ruhstaller T, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005; 16:762-6.
19. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
20. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24:394-400.
21. Wein A, Riedel C, Kockerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001; 12:1721-7.
22. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62:195-201.
23. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13:58-65.
24. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-71
25. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101:1033-8.
26. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
27. Garufi C, Torsello A, Tumolo S, et al. Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial). Eur J Can-cer Supplements 2009; 7:348(P-6086).
28. Masi G, Loupakis F, Baldi G, et al. First-line irinotecan, oxaliplatin and infusional 5-FU/LV(FOLFOXIRI) in combination with bevacizumab (BV). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Sym-posium; January 25-27, 2008; Orlando, FL. Abstract 363.
29. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxali-platin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420-5.
30. Ychou M, Desseigne F, Thezenas S, et al. Preliminary results of a multicentre phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU + Irinotecan + Oxaliplatin) as first line treatment of metastatic colorectal cancer (mCRC) patients. Presented at: the American Society of Clinical Oncology: 2009 Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA Abstract 450.
31. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
32. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38-47.
33. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
34. Kopetz S, Abbruzzese JL, Eng C, et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18 suppl):165s (abstract 3579).
35. Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009; 9:112.
36. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxali-platin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-9.
37. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treat-ment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225-32.
38. Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study). Presented at: the American Society of Clinical Oncology: 2009 Gastrointestinal Cancers Sym-posium; January 15-17, 2009; San Francisco, CA. Abstract 296.
39. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leu-covorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
40. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20:1499-505.
41. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluoro-uracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24:4976-82.
42. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 2008; 26:4906-11.
43. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
44. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002; 21:149a (abstract 592).
45. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study com-paring adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20:1964-70.
46. Bathe OF, Ernst S, Sutherland F, et al. Neoadjuvant irinotecan (CPT-11), 5-fluo-rouracil (5-FU), and leucovorin (LV) for colorectal liver metastases: A means of selecting candidates for resection. Presented at: the American Society of Clinical Oncology: 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA. Abstract 194.
47. Kemeny N. Presurgical chemotherapy in patients being considered for liver resec-tion. Oncologist 2007; 12:825-39.
48. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7:109, discussion 116-7.
49. Chiappa A, Bertani E, Makuuchi M, et al. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepato-gastroenterology 2009; 56:829-34.
50. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26:1830-5.
51. Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastasis. J Clin Oncol 2008; 26:4862-3.
52. Lubezky N, Geva R, Shmueli E, et al. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? World J Surg 2009; 33:1028-34.
53. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052-61, discussion 61-4.
54. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver me-tastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-45.
55. Ng JK, Urbanski SJ, Mangat N, et al. Colorectal liver metastases contract centrip-etally with a response to chemotherapy: a histomorphologic study. Cancer 2008; 112:362-71.
56. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruc-tion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460-6.
57. Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy J Gastrointest Surg 2003; 7:1082-8.
58. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steato-hepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-72.
59. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983-90.
60. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemo-therapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243:1-7. (Pubitemid 43054046)
61. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbid-ity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247:118-24.
62. Zorzi D, Kishi Y, Maru DM, et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resec-tion for colorectal liver metastases. Presented at: the American Society of Clinical Oncology: 2009 Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract 295.
63. Masi G, Loupakis F, Fornaro L, et al. Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. J Clin Oncol 2008; 26(15 suppl):196s (abstract 4074).
64. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer me-tastases. Ann Surg Oncol 2009; 16:35-41.
65. Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96:1037-42.
66. Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009; 145:362-71.
67. Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 2005; 23:9063-6.
68. Tobelem G. VEGF: A key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology 2007; 2:153-64
69. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759-65.
70. Rivera F, Cunningham D, Berry S, et al. Efficacy and safety of bevacizumab with standard first-line fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer: FIRST BEAT Ann Oncol 2008; 19(suppl 6):vi17 (abstract O-029).
71. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not sig-nificantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26:5254-60.
72. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20:985-92.